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In this paper we reported the synthesis, the in vitro and the in vivo 
biological evaluation of linear pseudo-peptides incorporating the 
N-VGCC blocker tripeptide Phe-NMe-Leu-Tyr(OBz)-NtBu and the 
biphalin pharmacophore Tyr-D-Ala-Gly-Phe. The novel sequences 
have been designed by using amino acids of different length to 
join the two pharmacophores and explore the structure activity 
relationships of the novel compounds.  
The clinical management of chronic pain still represents a 
serious worldwide health problem. The currently available 
analgesic drugs are not always efficacious and pain control 
remains a large unmet therapeutic need. Opioid agonists are 
widely used for the treatment of moderate and severe pain; 
however, they have limited efficacy for neuropathic pain at 
tolerable doses. Recent findings in biological systems and 
clinical care showed that the “single-target” drugs can block or 
stimulate a specific target though not always produce the 
desired effect, because many compensatory paths are involved 
in their activity.
1-3 
Opioid drugs exert their activities through the stimulation of 
the µ-opioid receptors (MOR), which are responsible not only 
for the antinociceptive effect but also for a number of serious 
drawbacks, including the development of tolerance, physical 
dependence, addiction liability, urinary retention, constipation 
and respiratory depression, many of which are due to the up-
regulation/signal inactivation of the opioid receptors.
4
 
Therefore, there is a vivid interest in the development of bi- or 
multi-functional compounds to address the complex nature of 
pain associated to the hyperactivation of several pro-
nociceptive systems. Hybrid analgesic compounds may 
stimulate the opioid system in neuropathic pain and minimize 
the activation of compensatory pro-nociceptive systems in 
response to consecutive opioid administration.
5
  
In the past 30 years the N-type Voltage Gated Calcium 
Channels (VGCC) have been elected as strength targets for 
analgesic development since they are involved in both 
ascending and descending pain pathways. Among the VGCC 
located in the central nervous system (CNS), Cav2.1 and 
Cav2.2. are abundant in presynaptic nerve terminals and are 
principally involved in the neurotransmitter release.
6 
Cav2.2 
channels are highly concentrated in dorsal root ganglia cell 
bodies, in the spinal cord dorsal horn and play an essential role 
in the perception of pain. The nociceptive signal is propagated 
to spino-talamic tract neurons into the spinal cord dorsal horn, 
where Cav2.2 mediates calcium influx and promotes the 
release of substance P and glutamate neurotransmitters.
6
 
Dorsal horn expression of the Cav2.2 is upregulated 
contemporary to mechanical and thermal allodynia in rat 
chronic sciatic nerve constriction injury model of neuropathic 
pain, and its activity is modulated by G-protein coupled 
receptors (GPCR) activation, many of which are also targets for 
opioids, cannabinoids, neuropeptide Y and substance P.
7
  
Interestingly, MOR and VGCC are co-localized on overlapping 
population of neurons in pain modulating regions of the CNS, 
thus molecular hybrids targeting both of them are expected to 
produce synergism in terms of improved potency, while 
decreasing the unwanted side effects.
5,8
  
A multi-target molecule designed by the hybridization of 
Cav2.2 blocker and µ-opioid agonist, would be an ideal 
therapeutic candidate for chronic and neuropathic pain 
treatment. Recently, the venom peptide Ziconotide derived 
from marine cone snails Conus magus, has been approved by 
the US Food and Drug Administration (FDA) and the European 
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Medicines Agency (EMA) for treatment of patients with severe 
chronic pain refractory to other treatments.
9 
Ziconotide 
selectively inhibits Cav2.2 VGCC subtype resulting in analgesia 
in chronic pain states.
10 
Successful attempts by Dr. Hruby and 
Dr. Ballet to link the agonist opioid activity and CCK inhibitors 
in one bivalent ligand,
11,12
 stimulate us to design a series of 
analogues in which the opioid agonist enkephalin-like 
fragment is joined at the C-terminus to the N-terminus of a 
novel short ω-conotoxin pharmacophore H-PheN(Me)-Leu-
Tyr(OBn)-NHtBu to form a single peptide. We have selected 
the opioid pharmacophore Tyr-D-Ala-Gly-Phe basing on our 
previous papers on the super potent opioid peptide Biphalin.
13 
Biphalin has two pharmacophores derived from enkephalin’s 
sequence held together by a hydrazine spacer. This synthetic 
peptide is able to bind simultaneously µ- and δ-opioid 
receptors with good affinity due to their anatomical 
superimposition. Such approach has allowed to synthesize very 
potent opioid peptides, particularly suitable for the treatment 
of severe pain.
7,13
 
Polt et al. described synergism between µ- and δ-opioid 
receptors by the glycopeptide MMP-2200,
14
 Hruby et al. also 
reported the discovery of novel multifunctional ligands with 
μ/δ opioid agonist/neurokinin-1 (NK1) antagonist activities for 
the treatment of pain.
15
 Our group previously reported a multi 
target analgesic drug joining together a portion of the ω-
conotoxin pharmacophore and an opioid peptide, in order to 
obtain peptide 10 (Figure 1). The opioid agonist’s 
pharmacophore has been attached to the N-terminal fragment 
of the ω-conotoxin loop 2. However, the design was not 
entirely satisfactory since the potency of the pharmacophore 
blocking the VGCC channels was significantly lower than that 
of the opioid portion.
16
 In this study we have designed our 
novel bi-functional molecules by following different 
approaches showed schematically in Figure 2. The 
pharmacophores have been joined together following the i) 
overlapping pharmacophores approach to give compounds 5a-
b; ii) adjacent pharmacophores approach to give the 
compounds 6a-b and iii) linked pharmacophores approach to 
give the compounds 7-9. The novel N-VGCC blocker 
pharmacophore, namely H-Phe-N(Me)-Leu-Tyr(OBn)-NHtBu 
(IC50 8.369 nM Cav2.2; IC50 10.299 nM Cav3.2, unpublished 
data), was obtained by studying a series of modifications of 
the potent N-methyl-N-aralkyl-peptidylamine N-VGCC blocker, 
described by Hu et al.
17
 aimed to introduce an N-terminus 
group suitable for coupling to the opioid pharmacophore. It is 
worth noting that this modified fragment is 1000 times more 
active than the pharmacophore used in our previous design 
(Ser-Arg-Leu-Met-Tyr-NH2; EC50 = 80µM)
 16
  (Figure 1). 
 
   Opioid Pharmacophore -  ω-conotoxin pharmacophore 
Tyr-D-Ala-Gly-Phe-Ser-Arg-Leu-Met-Tyr-NH2 
Compound 10 
Figure 1. Bivalent peptide (10) previously described by Mollica et al.
16 
 
RESULTS AND DISCUSSION  
The final products 5-9 have been synthetized by using 
combined solid phase peptide synthesis (SPPS) and solution 
phase peptide approach. The two approaches have been used 
in order to avoid the amidation of long peptides by t-butyl 
amine, which is sterically hindered. The intermediate 
tripeptide 3 was prepared following the Fmoc-SPPS procedure 
reported by Mollica et al. by growing the peptide on 2-
Chlorotrityl chloride resin (Cl-CTC) (loading 0.60 mMol/g).
1825
 
t-Butylamide formation required N-Boc protection of the last 
amino acid, a mild acid cleavage with 1% of TFA was 
performed to cleave the peptide from the resin. Then 
tripeptide 3 was treated with t-butylamine in presence of 
EDC
.
HCl, HOBt anhydrous as coupling reagents and NMM as 
base in DCM for 24h, to give the corresponding t-butylamide in 
60% yield. The so obtained t-butylamide was deprotected at 
the N terminus, with a mixture of TFA:DCM = 1:1 at room 
temperature to obtain the corresponding peptide 4 as TFA salt 
(Figure 3). Peptide elongation was performed following the 
procedure previously described until to reach the complete 
sequence.
16
 Isolation of the intermediates was performed on 
silica gel chromatography. Final products 5-9 were obtained as 
TFA salts and purified in RP-HPLC following the procedure 
described in Methods. Products 5 and 6 have been isolated as 
two distinct diastereoisomers, namely 5a,b and 6a,b while 
products 7-9 were obtained as inseparable mixture. It has 
been previously reported that N-methylated residues are 
prone to give from none up to 40% of racemization during the 
coupling. In literature is reported that during the activation of 
protected N-methyl residues, racemization can take place 
through tautomerization of the oxazolonium ion leading to 
pseudo-aromatic structures.
19 
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Figure 2. Different approaches used to design the bivalent peptides reported in this paper.  
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Several racemization-free procedures were tested, such as the 
use of HATU and Oxyme/Osuc combination as coupling 
reagents,
20
 however, their effects were found to be negligible 
to reduce the racemization to less than 20%, for the 
intermediate compound 3. On the other hands, several other 
procedures may be applied in future to improve this synthetic 
step.
21
 All the final peptides have been identified by MS and 
1
H-NMR in DMSO-d6 (see SI). All peptides displayed affinity to 
MOR within the nanomolar range (Table 1) whereas 
compound 8 showed weak affinity for MOR and negligible 
affinity for DOR. Compounds 5a, 5b and 9 showed higher MOR 
selectivity whereas 6a and 6b were twice as selective towards 
DOR than MOR. Compound 7 displayed slightly higher 
selectivity for the MOR. The G-protein activity of the novel 
compounds was investigated in 10 µM concentration. Overall 
the 5-9 peptides showed week, but significant inverse agonist 
activity, indicated by lower [
35
S]GTPγS specific binding 
compared to basal activity (100 % → ~50-80 %, Figure 2S, SI). 
In case of 6a, 7 and 8 this activity was mediated by MOR, since 
DAMGO was able to significantly reduce the inverse agonist 
activity of these compounds (Figure 2S). For comparison 
DAMGO and IleDelt II selective ligands significantly increased 
the specific binding of the [
35
S]GTPγS compared to basal level, 
which demonstrates their well-documented agonist activity. 
Compounds 5a and 5b, which have the best binding affinity for 
MOR receptor, were selected for evaluation of the blocking 
activity on Cav2.2. 5a and 5b possess activity on Cav2.2 at low 
micromolar range (0.453 µM and 0.710 µM respectively), thus 
5a was selected for the in vivo tests. The in vivo formalin (FT) 
and tail flick (TF) tests were performed (Figure 4). Both the in 
vivo tests confirm that 5a is able to induce analgesia after i.t. 
administration. A close comparison of the analgesic effect can 
be done with the previously synthetized multi-target 
compound 10 reported by Mollica et al.
16
 (Figure 1 and 4). 
Both these compounds suffer of reduced potency and efficacy 
if compared to a full opioid agonist such as biphalin or 
DAMGO. The same pattern was found for the blocking activity 
toward Cav2.2 when compared to ziconotide.
22-25 
However, it 
is worth noting that the improvement of the antinociceptive 
effect recorded for compound 5a compared with that 
previously reported for compound 10 in the tail flick test, 
(Figure 4), may be either related to a higher potency to the 
Cav2.2 and/or to better tissue penetration and 
pharmacokinetic. Indeed, the calcium channel blocker activity 
of 5a is 200 times higher than that of compound 10. 
CONCLUSION 
The aim of this work was to develop a set of new molecules to 
prove the hypothesis that combining an opioid 
pharmacophore and a N-type calcium channel (Cav2.2) blocker, 
would enhance the overall analgesic activity of the resulting 
molecules by additive or synergistic effects. The design and 
development of these novel hybrids peptides fall in modern 
research of safe and potent analgesics based on a multi-target 
approach that may increase their efficacy, bioavailability, and 
could simplify the route of administration avoiding the well-
known side effects of the opiates. In vitro biological data 
showed that the pseudo tripeptide 4 containing natural 
phenylalanine at position 1, was active in the nanomolar range 
as blocking agent of the N-type calcium channels (Cav2.2), thus 
it was selected as Cav2.2 pharmacophore, in the preparation 
of bivalent compounds 5-9. Among them, the multi target 
compound 5a showed the best binding affinity for MOR, and a 
considerable activity as Cav2.2 blocker, about 200 folds than 
the activity of the parent peptide 10,
16 
but around 50 times 
less potent than the pharmacophore (4) alone.  
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Figure 3. Part A: SPPS. Part B: solution phase synthesis of the pseudo peptides 5a-b,6a-b,7-8-9.   
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Compound 5a was tested in vivo following i.t. administration. 
The analgesic potency of the novel compounds resulted 
moderate, demonstrating that these hybrid molecules deserve 
further investigation and design efforts.  
 
Table 1. Affinity values for DOR and MOR, Cav2.2 of 5-9 peptides in 
competition binding experiments.  
Compound (Ki)
µ   (Ki)δ Cav2.2 (IC50)
 
5a 12.0 nM  66.3 nM 453.0 nM 
5b 12.8 nM  79.5 nM 0.71 µM 
6a  140.9 nM  77.8 nM nd 
6b  95 nM  55.9 nM nd  
7  129.8 nM  209.8 nM nd 
8 218.4 nM not relevant
3
 nd 
9  61.6 nM 221.3 nM nd 
4 -- -- 8.37 nM  
YaGF-NH2 2.8 nM 300 nM -- 
Ziconotide -- -- 0.055 nM 
Homologous lig
1
 1.5 nM 3.8 nM -- 
1
: MOR: DAMGO; DOR: IleDelt II; 
2
: calculated with the Ki values; 
3
: The 
compound did not displace [
3
H]IleDelt II total specific binding to non-
specific binding level (0 %), the maximum inhibition was ~50% at 
highest applied concentrations. The values are reported as means of 
three independent experiments. nd = not determined. 
 
 
Figure 4. (a) Antinociceptive activity in the formalin test of ziconotide (Z, 0.1 
nmol), DAMGO (D, 0.1 nmol) 5a (5 nmol), 10 (5 nmol) and vehicle (V) after 
i.t. administration in mice (n = 10). The analgesic effects are evidenced by 
decreased licking (seconds, mean ± SEM) quantified from 0 to 10 min (early 
phase) and from 15 to 40 min (late phase) following formalin injection. 
Statistical significance was defined as p < 0.05 (****p < 0.0001 versus 
vehicle). (b) Time-response of the analgesic activity in the tail flick test of 
ziconotide (0.1 nmol), DAMGO (0.1 nmol), 5a (5 nmol) and 10 (5 nmol) after 
i.t. administration in mice (n = 8). The activity is reported as percentage of 
the maximum possible effect (% M.P.E.) ± SEM. Statistical significance was 
assumed at p<0.05 (*p<0.05, **p < 0.01; ***p < 0.001; ****p<0.0001).  
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